CLL International Prognostic Index
Age [years]
Clinical stage
Tap to select
Serum β2 microglobulin [mg/L]
IGHV mutational status
Tap to select
TP53 status
Tap to select
Answer all question to see the result
Επιπλέον πληροφορίες
Οδηγίες και παραπομπές
Προειδοποίηση
Αυτό το εργαλείο προορίζεται μόνο για εκπαιδευτικούς σκοπούς, δεν αντιπροσωπεύει και δεν αντικαθιστά επαγγελματικές συμβουλές. Αυτό το εργαλείο δεν πρέπει να χρησιμοποιείται για την παροχή ιατρικών διαγνώσεων ή/και ιατρικών θεραπειών.
General description
Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in the Western world and has a highly variable disease course. The International prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI) integrates genetic, biological and clinical variables to stratify patients with chronic lymphocytic leukemia (CLL) into 4 risk groups with different prognostic implications and thus facilitates therapeutic decisions.
The CLL-IPI is a part of the ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with CLL.
Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in the Western world and has a highly variable disease course. The International prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI) integrates genetic, biological and clinical variables to stratify patients with chronic lymphocytic leukemia (CLL) into 4 risk groups with different prognostic implications and thus facilitates therapeutic decisions.
The CLL-IPI is a part of the ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with CLL.
References
An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17(6):779-90.
Έκδοση
1
Σχετικά με αυτό το εργαλείο
Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in the Western world and has a highly variable disease course. The International prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI) integrates genetic, biological and clinical variables to stratify patients with chronic lymphocytic leukemia (CLL) into 4 risk groups with different prognostic implications and thus facilitates therapeutic decisions.
The CLL-IPI is a part of the ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with CLL.
The CLL-IPI is a part of the ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with CLL.
